Amphastar Nanjing Pharmaceuticals
FDA inspection history in Nanjing, China, 2019
- 1
- Form 483
Every document, by year
- Form 483
2019: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2019One Form 483, at Nanjing, China.
Cited most
Across all Amphastar Nanjing Pharmaceuticals observations on file
- 21 CFR 211.170Reserve samples1
The complete Amphastar Nanjing Pharmaceuticals file.
All 1 documents as original PDFs. For supplier audits, diligence and inspection prep.
Sites
Nanjing, China
One Form 483 · 2019
Latest: Form 483, Oct 11, 2019 →
Documents
1 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2019-10-11 | 483 Form 483 | Nanjing, China | — | $99 |
Investigators on these documents
FEI number 3009805706 · most recent document Oct 11, 2019
About Amphastar Nanjing Pharmaceuticals
How many FDA Form 483s has Amphastar Nanjing Pharmaceuticals received?
FDA Intel has 1 Form 483 on file for Amphastar Nanjing Pharmaceuticals; the most recent is dated Oct 11, 2019.
When was Amphastar Nanjing Pharmaceuticals last inspected by FDA?
The most recent FDA inspection document on file for Amphastar Nanjing Pharmaceuticals is a Form 483 dated Oct 11, 2019, for the site in Nanjing, China.
What did FDA cite at Amphastar Nanjing Pharmaceuticals?
The regulations cited most in the observations on file for Amphastar Nanjing Pharmaceuticals are 21 CFR 211.170 (Reserve samples), 1 time.